EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines

Juan De Los Santos-Jiménez, Tracy Rosales, Bookyung Ko, José A Campos-Sandoval iD, Francisco J Alonso iD, Javier Márquez iD, Ralph J DeBerardinis, José M Matés iD

Cancers · 15.01.2023 · 15 (2) · 531

DOI: 10.3390/cancers15020531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.01.2023. Verfasst von Juan De Los Santos-Jiménez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Canceromics Laboratory, Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, 29010 Málaga, Spain. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Ministerio de Ciencia y Tecnología of Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most tumor cells can use glutamine (Gln) for energy generation and biosynthetic purposes. Glutaminases (GAs) convert Gln into glutamate and ammonium. In humans, GAs are encoded by two genes: GLS and GLS2. In glioblastoma, GLS is commonly overexpressed and considered pro-oncogenic. We studied the metabolic effects of inhibiting GLS activity in T98G, LN229, and U87MG human glioblastoma cell lines by using the inhibitor CB-839. We performed metabolomics and isotope tracing experiments using U-13C-labeled Gln, as well as 15N-labeled Gln in the amide group, to determine the metabolic fates of Gln carbon and nitrogen atoms. In the presence of the inhibitor, the results showed an accumulation of Gln and lower levels of tricarboxylic acid cycle intermediates, and aspartate, along with a decreased oxidative labeling and diminished reductive carboxylation-related labeling of these metabolites. Additionally, CB-839 treatment caused decreased levels of metabolites from pyrimidine biosynthesis and an accumulation of intermediate metabolites in the de novo purine nucleotide biosynthesis pathway. The levels of some acetylated and methylated metabolites were significantly increased, including acetyl-carnitine, trimethyl-lysine, and 5-methylcytosine. In conclusion, we analyzed the metabolic landscape caused by the GLS inhibition of CB-839 in human glioma cells, which might lead to the future development of new combination therapies with CB-839.

Schlagwörter

Stichwörter der Autor:innen

CB-839aspartatecancercancer metabolismcitrateglioblastomaglutaminaseglutaminemetabolic reprogrammingmetabolomics

Autor:innen und Institutionen

  • Canceromics Laboratory, Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, 29010 Málaga, Spain.
  • Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma BIONAND), Universidad de Málaga, 29010 Málaga, Spain.
  • Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: José A Campos-Sandoval, Francisco J Alonso, Javier Márquez, José M Matés

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • Ministerio de Ciencia y Tecnología of Spain
  • Junta de Andalucía
  • Howard Hughes Medical Institute, the National Cancer Institute
  • Ministerio de Ciencias, Innovación y Universidades

Zitieren

APA

De Los Santos-Jiménez, J., Rosales, T., Ko, B., Campos-Sandoval, J. A., Alonso, F. J., Márquez, J., DeBerardinis, R. J., & Matés, J. M. (2023). Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. Cancers, 15(2), 531. https://doi.org/10.3390/cancers15020531

Vancouver

De Los Santos-Jiménez J, Rosales T, Ko B, Campos-Sandoval JA, Alonso FJ, Márquez J, et al. Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. Cancers. 2023;15(2):531. doi:10.3390/cancers15020531

BibTeX
@article{DeLosSantosJimnez2023,
  author = {De Los Santos-Jiménez, Juan and Rosales, Tracy and Ko, Bookyung and Campos-Sandoval, José A and Alonso, Francisco J and Márquez, Javier and DeBerardinis, Ralph J and Matés, José M},
  title = {Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {531},
  doi = {10.3390/cancers15020531}
}
Kostenlos starten →